Research Article
Influence of SPK with Enteric Drainage on the Pancreatic Exocrine Function in Diabetic Patients with Uremia
Table 3
Clinical information of SPK and RT transplantation groups.
| | Transplantation | SPK () | RT () | |
| | Pancreatic cold ischemic time (h), median (IQR) | 6 (6-7) | — | — | | Renal cold ischemia time (h), median (IQR) | 4 (3–5) | 8 (5–9) | 0.000 | | HLA mismatch, median (IQR) | 2 (2-3) | 3.0 (2.0-3.3) | 0.693 | | Negative lymphocytotoxicity, n (%) | 19 (100) | 22 (100) | — | | Immunosuppressive regimen, n (%) | | | <0.001 | | FK506 + MMF + Pred | 17 (89.5) | 3 (13.6) | | | CsA + MMF + Pred | 2 (10.5) | 15 (68.2) | | | RAPA + MMF + Pred | 0 (0.0) | 4 (18.2) | | | Induction regimen, n (%) | | | <0.001 | | Simulect | 2 (10.5) | 20 (90.9) | | | ATG | 17 (89.5) | 2 (9.1) | |
|
|
SPK: simultaneous pancreas–kidney transplantation; RT: diabetic patients with uremia who underwent renal transplantation; HLA: human leucocyte antigen; FK506: tacrolimus; MMF: mycophenolate mofetil; Pred: prednisone; CsA: ciclosporin; RAPA: rapamycin; ATG: rabbit anti-human thymocyte globulin.
|
